Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bone graft & orthobiologics cases in Mississippi: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 12% on average (190 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 299 | 22% |
| 2020 | 7 | 194 | 25% |
| 2021 | 6 | 163 | 32% |
| 2022 | 6 | 150 | 37% |
| 2023 | 5 | 131 | 42% |
| 2024 | 5 | 119 | 46% |
| 2025 from claims | – | 91 74–107 | 47% |
| 2026 forecast | – | 91 71–114 | 48% |
| 2027 forecast | – | 91 67–120 | 49% |
| 2028 forecast | – | 90 64–124 | 50% |
| 2029 forecast | – | 90 61–128 | 51% |
| 2030 forecast | – | 89 58–132 | 52% |
Graft add-on codes identify surgeons using biologics across spine and extremity cases. Professional codes (what the surgeon bills): CPT 20930, 20931, 20936, 20937, 20938, 20939.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Mississippi; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 54% inpatient hospital, 35% hospital outpatient, 11% surgery center. The share outside the hospital has moved +9 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 52 | 1,980−11%/yr | −11%/yr | 0.9 | 3% | 1,960 in 2030−0.1%/yr |
| Florida | 34 | 1,353−8.3%/yr | −8.3%/yr | 0.6 | 6% | 1,490 in 2030+1.6%/yr |
| Georgia | 15 | 773−3.8%/yr | −3.8%/yr | 0.9 | 5% | 720 in 2030−1.3%/yr |
| Virginia | 17 | 601−14%/yr | −14%/yr | 0.6 | 0% | 650 in 2030+1.2%/yr |
| North Carolina | 14 | 525−14%/yr | −14%/yr | 0.5 | 2% | 520 in 2030−0.2%/yr |
| Tennessee | 16 | 498−9.2%/yr | −9.2%/yr | 0.7 | 3% | 450 in 2030−1.8%/yr |
| Arkansas | 8 | 484−8.7%/yr | −8.7%/yr | 1.2 | 2% | 370 in 2030−4.3%/yr |
| Maryland | 14 | 451−8%/yr | −8%/yr | 0.5 | 4% | 370 in 2030−3.3%/yr |
| South Carolina | 13 | 440−13%/yr | −13%/yr | 0.6 | 1% | 450 in 2030+0.5%/yr |
| Oklahoma | 13 | 397−18%/yr | −18%/yr | 0.8 | 1% | 430 in 2030+1.3%/yr |
| Louisiana | 8 | 369−1.6%/yr | −1.6%/yr | 0.9 | 1% | 360 in 2030−0.5%/yr |
| Delaware | 7 | 334−2.8%/yr | −2.8%/yr | 1.9 | 11% | 340 in 2030+0.5%/yr |
| Alabama | 10 | 293−20%/yr | −20%/yr | 0.6 | 4% | 290 in 20300%/yr |
| Kentucky | 7 | 228−18%/yr | −18%/yr | 0.5 | 0% | 260 in 2030+2.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 171 | 53,180+8.6%/yr | +8.6%/yr | 136.31.2× | 38% | 92,200 in 2030+9.6%/yr |
| Skin substitutes & wound grafts | 39 | 8,487+28%/yr | +28%/yr | 15.31.4× | 68% | 14,900 in 2030+9.8%/yr |
Bone graft & orthobiologics in every state, and its device makers · Every procedure market in Mississippi · Every state · Compare with Texas
Bausch & Lomb leads with 56% of company spending on these surgeons in 2025, +18 pts on 2024.
In 2025, 10 companies reported engagement with Mississippi’s surgeons worth $29K in consulting, speaking, meals and travel tied to these products, about $5,775 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.